A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus

NCT02305810 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Neuroendocrine Tumour Metastatic

Interventions

DRUG: Everolimus 10 mg daily

Sponsor

European Institute of Oncology